SCHEMBL31475876

SCHEMBL31475876

Cc1cc(N)ccc1Oc1ccc2c(c1)nnn2C(F)F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 1/20 0.34
HCAR3 P49019 4/20 0.32
HPGD P15428 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
EGFR P00533 1/20 0.31
ERBB2 P04626 1/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
FGFR1 P11362 1/20 0.31
HTR2A P28223 1/20 0.30
SLC6A4 P31645 1/20 0.30
PDE2A O00408 1/20 0.30
PDE10A Q9Y233 1/20 0.30
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
THRB P10828 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31476211 0.84 HPGD (0.31) HCAR3HPGDHCAR2
SCHEMBL24569481 0.83 HCAR3 (0.40) L3MBTL1KDM4ENPC1HCAR3HPGD
SCHEMBL31475934 0.81 L3MBTL1 (0.34) L3MBTL1KDM4ENPC1HCAR3EGFR
SCHEMBL31475900 0.80 HCAR3 (0.43) L3MBTL1KDM4ENPC1HCAR3MAPT
SCHEMBL29888093 0.80 KDM4E (0.35) L3MBTL1KDM4ENPC1HCAR3EGFR
SCHEMBL31475721 0.79 FGFR1 (0.41) KDM4EHCAR3HPGDEGFRERBB2
SCHEMBL31257435 0.75 L3MBTL1 (0.42) L3MBTL1KDM4ENPC1HCAR3HPGD
SCHEMBL1191996 0.73 KMT2A (0.46) KDM4EHPGDEGFRERBB2ALDH1A1
SCHEMBL24569522 0.72 HCAR3 (0.39) L3MBTL1KDM4ENPC1HCAR3HPGD
SCHEMBL2992329 0.71 ALDH1A1 (0.52) KDM4ENPC1HPGDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR L3MBTL1 475/4885KDM4E 1834/4885NPC1 2944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.